Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 39

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 39
---
, at no cost, by writing or telephoning us at:

<div align='center'>Edesa Biotech, Inc.

Attention: Investor Relations

100 Spy Court

Markham

Ontario L3R 5H6 Canada

Tel. (289) 800-9600</div>

| S-26 |

You should rely only on the information
contained in this prospectus supplement, including information incorporated by reference as described above. We have not authorized anyone
else to provide you with different information. You should not assume the information in this prospectus supplement or the accompanying
prospectus is accurate as of any date other than the date on the front of those documents or that any document incorporated by reference
is accurate as of any date other than its filing date. You should not consider this prospectus to be an offer or solicitation relating
to the securities in any jurisdiction in which such an offer or solicitation relating to the securities is not authorized. Furthermore,
you should not consider this prospectus supplement to be an offer or solicitation relating to the securities if the person making the
offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or solicitation.

| S-27 |

PROSPECTUS

<div align='center'>Edesa Biotech, Inc.

$150,000,000

Common Shares

Preferred Shares

Warrants

Debt Securities

Subscription Rights

Units</div>

We may offer, issue and sell from time to time together or separately, in one or more offerings, any combination of (i) our common shares, (ii) our preferred shares, which we may issue in one or more series, (iii) warrants, (iv) senior or subordinated debt securities, (v) subscription rights and (vi) units. The debt securities may consist of debentures, notes or other types of debt. The debt securities, preferred shares, warrants and subscription rights may be convertible into, or exercisable or exchangeable for, common shares, preferred shares or other securities of ours. The units may consist of any combination of the securities listed above.

We may offer these securities in amounts, at prices and on terms determined at the time of offering. We may sell the securities directly to you, through agents we select, or through underwriters and dealers we select. If we use agents, underwriters or dealers to sell the securities, we will name them and describe their compensation in a prospectus supplement.

Our common